Ontology highlight
ABSTRACT: Background
Pyrazinamide and fluoroquinolones are essential antituberculosis drugs in new rifampicin-sparing regimens. However, little information about the extent of resistance to these drugs at the population level is available.Methods
In a molecular epidemiology analysis, we used population-based surveys from Azerbaijan, Bangladesh, Belarus, Pakistan, and South Africa to investigate resistance to pyrazinamide and fluoroquinolones among patients with tuberculosis. Resistance to pyrazinamide was assessed by gene sequencing with the detection of resistance-conferring mutations in the pncA gene, and susceptibility testing to fluoroquinolones was conducted using the MGIT system.Findings
Pyrazinamide resistance was assessed in 4972 patients. Levels of resistance varied
SUBMITTER: Zignol M
PROVIDER: S-EPMC5030278 | biostudies-literature | 2016 Oct
REPOSITORIES: biostudies-literature